IOVA Iovance Biotherapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IOVA

Price (delayed)

$4.44

Market cap

$1.98B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.92

Enterprise value

$1.83B

?
Relative Growth: Rel. Growth: 44
Relative Strength: Rel. Strength: 86
Relative Valuation: Rel. Valuation: 13
Relative Profitability: Rel. Profitability: 18

Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy ...

Highlights
The gross profit has soared by 51% YoY and by 16% from the previous quarter
IOVA's revenue is up by 34% YoY and by 8% QoQ
The company's quick ratio fell by 13% YoY but it rose by 11% QoQ
IOVA's equity is down by 6% year-on-year but it is up by 3.3% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.iovance.com

Key stats

What are the main financial stats of IOVA

IOVA stock price

How has the Iovance Biotherapeutics stock price performed over time
Intraday
17.15%
1 week
3.26%
1 month
15.32%
1 year
142.62%
YTD
62.64%
QTD
26.5%

Financial performance

How have Iovance Biotherapeutics's revenue and profit performed over time
Revenue
$285.61M
Gross profit
$104.86M
Operating income
-$363.18M
Net income
-$353.86M
Gross margin
36.7%
Net margin
-123.9%
The gross profit has soared by 51% YoY and by 16% from the previous quarter
IOVA's revenue is up by 34% YoY and by 8% QoQ
The operating margin is up by 32% YoY and by 17% from the previous quarter
Iovance Biotherapeutics's net margin has increased by 30% YoY and by 17% from the previous quarter

Price vs fundamentals

How does IOVA's price correlate with its fundamentals

Growth

What is Iovance Biotherapeutics's growth rate over time

Valuation

What is Iovance Biotherapeutics stock price valuation
P/E
N/A
P/B
2.53
P/S
6.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.4
The EPS has grown by 25% YoY and by 16% from the previous quarter
IOVA's price to book (P/B) is 54% more than its last 4 quarters average of 1.4 but 30% less than its 5-year quarterly average of 3.1
IOVA's equity is down by 6% year-on-year but it is up by 3.3% since the previous quarter
The price to sales (P/S) is 54% higher than the last 4 quarters average of 3.6
IOVA's revenue is up by 34% YoY and by 8% QoQ

Efficiency

How efficient is Iovance Biotherapeutics business performance
The ROS has grown by 30% YoY and by 17% from the previous quarter
Iovance Biotherapeutics's ROIC has decreased by 9% YoY but it has increased by 6% from the previous quarter
The ROE is up by 8% since the previous quarter
The return on assets has increased by 8% since the previous quarter

Dividends

What is IOVA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IOVA.

Financial health

How did Iovance Biotherapeutics financials performed over time
The current ratio has decreased by 14% YoY but it has increased by 13% from the previous quarter
The company's quick ratio fell by 13% YoY but it rose by 11% QoQ
Iovance Biotherapeutics's debt is 93% less than its equity
Iovance Biotherapeutics's debt has decreased by 11% YoY and by 3.4% from the previous quarter
IOVA's equity is down by 6% year-on-year but it is up by 3.3% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.